Application of heparin-binding protein detection in respiratory infectious diseases

 The bactericidal ability of HBP as well as the heparin-binding ability are related to its strong positive charge. HBP, as a chemotactic substance, can activate monocytes and macrophages, induce vascular leakage and tissue edema. Inactivating HBP blocks endothelial hyperosmocyte hyperpermeability caused by neutrophils.

At present, HBP, as an acute phase protein, is an effective biomarker to assess the severity of disease in patients with sepsis, and is more important in the early diagnosis and efficacy monitoring of patients with septic shock. In recent years, several studies have shown that in addition to being used in the early diagnosis of sepsis, high quality Clinical Chemistry HBP Reagent Kit has certain clinical significance in the diagnosis and prediction of respiratory diseases.

 

HBP, PCT, CRP poct rapid test all have certain predictive significance for AECOPD, and HBP has the best prediction results. In patients with thick sputum or requiring mechanical ventilation who were admitted to the hospital due to acute exacerbations, the values of HBP, PCT, CRP were more obvious.

 

• EARLY DETECTION OF HBP COMBINED WITH APACHEII. SCORE CAN ASSIST IN THE DIAGNOSIS IN TIME, WHICH IS HELPFUL TO IMPROVE THE EFFECTIVENESS OF EARLY TREATMENT OF MDRO INFECTED VAP.

• Serum HBP rapid test is helpful for early evaluation of SIVP patients with ARDS, and also helps to predict the prognosis of patients with SIVP and ARDS, and high serum HBP is a risk factor for the prognosis of patients with SIVP and ARDS.
• In addition, recent prospective studies of severe COVID-19 have found that HBP levels in patients with severe COVID-19 infection are elevated before the onset of organ dysfunction, suggesting that HBP can be used as a prognostic marker for such patients.

HBP is elevated earlier in the acute phase than other common inflammatory markers and can identify co-infections in patients with interstitial lung disease (ILD). HBP may be predictive of acute exacerbations of ILD due to the mechanism of pre-release. These findings suggest that HBP is more advantageous in assessing the rapid progression and prognosis of interstitial lung disease exacerbations (AE-ILDs). It has the potential to be a novel adjunctive marker in the evaluation of patients with ILD.

 

As one of the inflammatory markers, HBP can be rapidly increased in minor bacterial infections, which is of great significance for the early diagnosis of sepsis and the prediction of septic shock. As an acute phase protein, HBP has certain relevance in the early diagnosis, disease development and prediction of respiratory system-related infectious diseases. HBP plays an important role in individual testing and has also shown its advantages in combination with other indicators.